1. Home
  2. QNCX vs ASMB Comparison

QNCX vs ASMB Comparison

Compare QNCX & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quince Therapeutics Inc.

QNCX

Quince Therapeutics Inc.

HOLD

Current Price

$28.98

Market Cap

17.5M

Sector

Health Care

ML Signal

HOLD

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

HOLD

Current Price

$25.53

Market Cap

512.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QNCX
ASMB
Founded
2012
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.5M
512.1M
IPO Year
2019
2010

Fundamental Metrics

Financial Performance
Metric
QNCX
ASMB
Price
$28.98
$25.53
Analyst Decision
Hold
Strong Buy
Analyst Count
2
5
Target Price
N/A
$44.20
AVG Volume (30 Days)
15.8K
300.5K
Earning Date
04-10-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
91.78
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$638.39
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.08
$21.80
52 Week High
$35.41
$39.71

Technical Indicators

Market Signals
Indicator
QNCX
ASMB
Relative Strength Index (RSI) 54.79 33.83
Support Level $29.95 $21.80
Resistance Level $35.38 $29.99
Average True Range (ATR) 2.10 1.87
MACD -0.56 -1.24
Stochastic Oscillator 62.36 6.90

Price Performance

Historical Comparison
QNCX
ASMB

About QNCX Quince Therapeutics Inc.

Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

Share on Social Networks: